Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Preventing errors with neuromuscular blocking agents.

Judy L Smetzer1, Michael R Cohen

  • 1Institute for Safe Medication Practices, Huntingdon Valley, Pennsylvania, USA.

Joint Commission Journal on Quality and Patient Safety
|March 7, 2006
PubMed
Summary

Recommendations focus on reducing harm from high-alert neuromuscular blocking agents. Proper use is crucial to prevent severe patient injury or death associated with these potent medications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Key Vulnerabilities in the Surgical Environment: Container Mix-Ups and Syringe Swaps Do Not Confuse Idarucizumab with Idarubicin.

Hospital pharmacy·2024
Same author

Avoid Using the Error-Prone Abbreviation "TPA"; Unexpected Painful Breath; Mix-ups among "V" Drugs; <i>Brintellix-Brilinta</i>: Name Change Needed.

Hospital pharmacy·2024
Same author

Methylene Blue is a Monoamine Oxidase Inhibitor; Severe Harm and Death Associated with Low-Dose Methotrexate; Potentially Dangerous Mix-up between Cancer Drugs.

Hospital pharmacy·2024
Same author

Beyond mixed case lettering: reducing the risk of wrong drug errors requires a multimodal response.

BMJ quality & safety·2022
Same author

Correction to: Strategies to Reduce Errors Associated with 2‑Component Vaccines.

Pharmaceutical medicine·2021
Same author

Strategies to Reduce Errors Associated with 2-Component Vaccines.

Pharmaceutical medicine·2020

Area of Science:

  • Pharmacology
  • Patient Safety
  • Clinical Practice

Background:

  • Neuromuscular blocking agents (NMBAs) are critical in anesthesia and intensive care.
  • These drugs carry a high risk of serious adverse events if misused.
  • Existing protocols may not sufficiently mitigate harm from NMBAs.

Purpose of the Study:

  • To provide evidence-based recommendations for reducing harm associated with NMBAs.
  • To enhance the safe use of high-alert neuromuscular blocking agents in clinical settings.
  • To minimize the incidence of catastrophic injuries or death due to NMBA misuse.

Main Methods:

  • Review of existing literature on NMBA safety and adverse events.
  • Analysis of reported incidents involving neuromuscular blocking agents.

Related Experiment Videos

  • Development of consensus-based recommendations for safe administration and monitoring.
  • Expert panel review of proposed guidelines.

    • Main Results:

    • Identification of key risk factors contributing to NMBA-related harm.
    • Formulation of specific strategies for risk reduction, including enhanced monitoring and standardized protocols.
    • Emphasis on comprehensive training for healthcare professionals administering NMBAs.
    • Guidelines for emergency management of NMBA-related complications.

    Conclusions:

    • Implementing these recommendations can significantly decrease the risk of harm from neuromuscular blocking agents.
    • Adherence to guidelines is essential for preventing severe patient outcomes.
    • Continuous evaluation of NMBA safety practices is necessary to ensure optimal patient care.